An early study of the drug figitumumab has found that in some patients it can curb the growth of Ewing’s sarcoma – a cancer which affects mainly teenage boys. The study was led by Dr Johann de Bono, from The Institute of Cancer Research and The Royal Marsden Hospital, and funded by Pfizer, who developed the drug.
Ewing’s sarcoma is a rare disease in which cancer cells are found in the bone or soft tissue, most often the pelvis, femur, humerus and ribs. It is more common in males than females, and most often develops between the ages of 10 to 20.
Previous studies have shown that a molecule called insulin-like growth-factor-1 receptor (IGF-1R) is involved in the growth and spread of Ewing’s sarcoma and other sarcoma subtypes. Figitumumab is an antibody that blocks IGF-1R and so scientists investigated whether this drug could be used to treat Ewing’s sarcoma and other sarcomas.
Between January 2006 and August 2008, a Phase I trial was carried out to assess whether the drug was safe for sarcoma patients. Figitumumab was given to 29 patients with advanced sarcomas who were responding poorly to conventional treatments, including 16 patients with Ewing’s sarcoma. Six patients were aged 18 years or younger, and the median age was 30. The patients had already tried on average three cycles of chemotherapy, 21 had been given radiotherapy and 20 had already undergone surgery.
Side effects were mostly mild to moderate (grade one and two). More serious side effects that required treatment, back pain, vomiting and deep vein thrombosis (grade three), were each noted once in individual patients; a blood test showed one patient had high levels of liver enzymes; and one patient had high concentrations of uric acid (grade four).
Twenty eight patients were also able to be assessed to determine whether their cancer responded to the drug. Scans showed one Ewing’s sarcoma patient was free of cancer after treatment, a second Ewing’s sarcoma patient’s tumour shrunk, and tumours stabilised for at least four months in a further six patients. Among non-Ewing’s sarcoma patients, tumours also stabilised for around nine months in one patient with fibrosarcoma and a second patient with synovial sarcoma.
Dr de Bono says: “Our results show this drug can be safe for both children and adults with sarcoma. Although this trial was designed just to measure safety, for most patients we were also able to measure the drug’s effect on their tumours. We found cancer shrank or stabilised for patients with several sarcoma subtypes, including about half of the patients with Ewing’s sarcoma.”
“Larger Phase II trials of this drug have just finished recruiting at multiple centres around the world, including a trial in Ewing’s sarcoma patients involving our colleagues at the ICR and the Royal Marsden. We look forward to assessing these results.”
The study was a collaboration between the ICR and The Royal Marsden in the UK and the Mayo Clinic, the University of Michigan Cancer Centre and Pfizer Global Research and Development in the US.
Media Contact: ICR Science Press Officer Jane Bunce, or 0207 153 5106 or after hours 077217 47900
The Institute of Cancer Research (ICR)
- The ICR is Europe’s leading cancer research centre
- The ICR has been ranked the UK’s top academic research centre, based on the results of the Higher Education Funding Council’s Research Assessment Exercise
- The ICR works closely with partner The Royal Marsden NHS Foundation Trust to ensure patients immediately benefit from new research. Together the two organisations form the largest comprehensive cancer centre in Europe
- The ICR has charitable status and relies on voluntary income, spending 95 pence in every pound of total income directly on research
- As a college of the University of London, the ICR also provides postgraduate higher education of international distinction
- Over its 100-year history, the ICR’s achievements include identifying the potential link between smoking and lung cancer which was subsequently confirmed, discovering that DNA damage is the basic cause of cancer and isolating more cancer-related genes than any other organisation in the world
- The ICR is home to the world’s leading academic drug development team. Several important anti-cancer drugs used worldwide were synthesised at the ICR and it has discovered an average of two preclinical candidates each year over the past five years
- For more information visit www.icr.ac.uk
The Royal Marsden Hospital
- The Royal Marsden opened its doors in 1851 as the world’s first hospital dedicated to cancer treatment, research and education. The hospital is based in Chelsea, London and Sutton, Surrey.
- Today, together with its academic partner, The Institute of Cancer Research, it is the largest and most comprehensive cancer centre in Europe treating over 40,000 patients every year. It is a centre of excellence, and the only NHS Trust to achieve the highest possible ranking in the Healthcare Commission’s Annual Health Check for the third year in a row.
- Since 2004, the hospital’s charity, The Royal Marsden Cancer Campaign, has helped raise over £43 million to build theatres, diagnostic centres, and drug development units.
- Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital.
- For more information visit www.royalmarsden.nhs.uk.